Cleveland BioLabs, U.S. Department of Defense other news

Cleveland BioLabs received a $14.8 million contract from the DoD to develop CBLB502 to treat acute radiation syndrome (ARS). The agency has an option to purchase up to $30 million worth of CBLB502 if ...